The treatment of prostate cancer is always planned on an individual basis, depending of the nature of the disease. The choice of treatment depends on possible other diseases, any evidence of high-risk prostate cancer, the results of staging and, naturally, the patient’s own preferences.
Localised prostate cancer can be cured with radiotherapy or surgery. Depending on the nature of the cancer, radiotherapy can be customised in a number of ways. External radiotherapy provides many techniques to choose from, and brachytherapy (internal radiotherapy) is also an option. In aggressive cancers, best results are probably achieved by combining external radiotherapy with high-dose-rate (HDR) brachytherapy. Depending on the risk factors, radiotherapy can also be combined with hormonal therapy.
Patients receiving prostate cancer treatment are recommended to see a urotherapist or physiotherapist or a specialist in areas such as nutrition and sexual therapy. They can provide home care instructions related to, for example, recovery-promoting exercises and general well-being.
Docrates operates also in the field of clinical drug studies. We have participated in 30 different clinical drug trials so far.
Treating advanced prostate cancer requires multidisciplinary expertise and various treatment methods
In addition to the traditional prostate cancer treatments, we offer radionuclide therapies with, for example, radium-223 and samarium. We also added lutetium-PSMA to our treatment portfolio at the beginning of 2017. Radionuclide therapy with a radioactive substance (radium or samarium) that targets the bones has been found to be both an effective and safe treatment option, when metastases exist only in bone structures. The lutetium-PSMA therapy also makes it possible to effectively destroy metastases outside the bone structures, without serious adverse effects.
Using HDR brachytherapy in addition to conventional external radiotherapy in high-risk and locally metastatic prostate cancer enables us to increase the radiation dose while minimising the probability of adverse effects.
*Lutetium-PSMA is still experimental treatment, and has a special permission for compassionate use by the Finnish Medicines Agency (Fimea). The international randomised controlled trials are also in their third phase, after which official and more detailed Current Care Guidelines can probably be issued for the cancer cases selected for treatment. However, some results were already presented in October’s ESMO2018 conference, according to which the dose escalation study had shown that even a dose three times larger than that proved effective at Docrates was found safe and well tolerated without the appearance of the toxicity that restricts the dosage. Read more about treatment of advanced prostate cancer here.